key: cord-0787522-b72hj1j1
authors: Ssentongo, Paddy; Heilbrunn, Emily S.; Ssentongo, Anna E.; Advani, Shailesh; Chinchilli, Vernon M.; Nunez, Jonathan J.; Du, Ping
title: Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis
date: 2021-03-18
journal: Sci Rep
DOI: 10.1038/s41598-021-85359-3
sha: f420c112e8537ae251e816011fca1f175a2a377b
doc_id: 787522
cord_uid: b72hj1j1

Susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the risk of mortality among people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLWHA) is largely unknown. PLWHA are unique due to their altered immune system from their history of chronic HIV infection and their use of antiretroviral therapy, some of which have been used experimentally to treat coronavirus disease 2019 (COVID-19). Therefore, we conducted a systematic review and meta-analysis to assess the epidemiology of SARS-COV-2/HIV coinfection and estimate associated mortality from COVID-19 (Prospero Registration ID: CRD42020187980). PubMed, SCOPUS, OVID and Cochrane Library databases, and medRxiv preprint repositories were searched from January 1, 2020, to December 12, 2020. Data were extracted from studies reporting COVID-19 attack and mortality rates in PLWHA compared to their HIV-negative counterparts. Pooled attack and mortality risks were quantified using random-effects models. We identified 22 studies that included 20,982,498 participants across North America, Africa, Europe, and Asia. The median age was 56 years, and 50% were male. HIV-positive persons had a significantly higher risk of SARS-CoV-2 infection [risk ratio (RR) 1.24, 95% CI 1.05–1.46)] and mortality from COVID-19 (RR 1.78, 95% CI 1.21–2.60) than HIV-negative individuals. The beneficial effects of tenofovir and protease-inhibitors in reducing the risk of SARS-CoV-2 infection and death from COVID-19 in PLWHA remain inconclusive. HIV remains a significant risk factor for acquiring SARS-CoV-2 infection and is associated with a higher risk of mortality from COVID-19. In support of the current Centers for Disease Control and Prevention (CDC) guidelines, persons with HIV need priority consideration for the SARS-CoV-2 vaccine.

www.nature.com/scientificreports/ storm observed in patients with COVID-19 8 . With nearly 40 million PLWHA across the globe, it remains urgent to characterize the epidemiology and outcomes of COVID-19 such as intensive care unit (ICU) admission, mechanical ventilation, and death among this group 9 .

To address this knowledge gap, we conducted a systematic review and meta-analysis of the literature to (1) assess the risk of SARS-CoV-2 infection among PLWHA and (2) estimate the mortality risk from COVID-19 for PLWHA.

Information source, search strategy, and study selection. The present study has been registered with PROSPERO (registration ID: CRD42020187980) and is reported per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplemental Table 1) 10 . We searched PubMed, Scopus, OVID, Web of Science, and Cochrane Library from January 1, 2020 to December 12, 2020 . In addition, we searched grey literature using Google Scholar and Medrxiv servers to identify any preprints or associated publications. Furthermore, we performed hand-searching of the reference lists of included studies, relevant reviews, or other relevant documents. Studies reporting susceptibility and death from COVID-19 in people with and without HIV infections were included in our search and analysis. We did not limit the search to study design, country of publication, or language to provide a comprehensive landscape of the COVID-19 infection. Articles published in other languages were appropriately translated and further included/excluded during the screening process.

The primary outcome was susceptibility to SARS-CoV-2 among PLWHA compared to their HIV-negative counterparts. A secondary outcome was the mortality risk of COVID-19 patients with HIV compared to COVID-19 patients without HIV. Predefined search terms determined by the Medical Subject Headings (MeSH) included multiple combinations of the following: "Human Immunodeficiency Virus" OR "HIV" OR "AIDS", AND "COVID-19" OR "Coronavirus. " Studies found as a result of our initial search were transferred into Endnote, which further removed duplicate studies.

Eligibility criteria. Studies were selected according to the following criteria: participants, condition or outcome(s) of interest, study design and context.

CoV-2, regardless of age, country, or antiretroviral therapy. Data extraction. Two investigators (ESH and AES) individually screened all titles and abstracts against the inclusion criteria. Articles were coded as "yes" or "no" for inclusion or exclusion. If both reviewers coded an article as "yes", it was included for full-text review, if both reviewers coded as "no", it was removed from the further screening process, and if there was a discrepancy, then decision was reached through mutual consensus with a third investigator (PS). After initially screening articles for inclusion based on titles and abstracts, ESH and AES then screened full-text articles. Disagreements were resolved by discussion to meet a consensus, if necessary. In scenarios where consensus was not reached, disagreements were resolved by a third investigator (PS). We extracted the following information: year of publication, date of the study, sample size, rates of COVID-19 in HIV-positive and negative individuals, mortality rates, proportion on mechanical ventilators and ICU admissions. Relevant effect size estimates, such as the relative risk, odds ratios or hazard ratios of mechanical ventilation, ICU admission, and death were extracted as well.

Study quality assessment. Two investigators (ESH and AES) independently assessed the quality of the included studies. The Newcastle-Ottawa Scale (NOS) was utilized for the quality assessment of the included studies 11 . NOS scale rates observational studies based on 3 parameters: selection, comparability between the exposed and unexposed groups, and exposure/outcome assessment. It assigns a maximum of 4 stars for selection, 2 stars for comparability, and 3 stars for exposure/outcome assessment. Studies with less than 5 stars were considered low quality, 5 to 7 stars moderate quality, and more than 7 stars high quality.

Data synthesis and statistical analysis. A narrative approach was used to describe the number of studies, study settings, diagnostic criteria COVID-19 (laboratory-confirmed by polymerase chain reaction (PCR) of SARS-CoV-2 RNA or clinical diagnosis), ARV therapy such as nucleos(t)ide reverse transcriptase inhibitors (NRTI), (e.g., tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, lamivudine), non-nucleoside reverse transcriptase inhibitors (NRTI), (e.g., doravirine); protease-inhibitors (e.g., darunavir, lopinavir or ritonavir), integrase inhibitors (e.g., dolutegravir), CD4 count, HIV viral load, pre-existing comorbidities (i.e. can- www.nature.com/scientificreports/ cer, diabetes, cardiovascular disease, hypertension, heart failure, chronic kidney disease, chronic liver disease, asthma, and obesity) and study-level patient demographics. The metaprop and metagen functions from the R package meta were used to calculate the pooled effect estimates using random-effects models 12 . DerSimonian and Laird random-effects method was applied to estimate the pooled between-study variance (heterogeneity) 13 . RR of SARS-CoV-2 among PLWHA compared to HIVnegative individuals were estimated. Also, estimated were RRs for COVID-19 mortality, ICU admissions, and use of ventilation. Individual and pooled estimates were graphically displayed using forest plots. Between-study heterogeneity was assessed with I 2 statistics, expressed as percent low (25%), moderate (50%), and high (75%) and Cochrane's Q statistic (significance level < 0.05) 14 . To investigate the sources of heterogeneity, subgroup analysis was performed by country of the study. Potential ascertainment bias was assessed qualitatively with funnel plots, by plotting the study effect size against standard errors of the effect size, and quantitatively with the Egger's test 15 . Results were reported as RR or prevalence expressed as a percentage. All statistical analyses were performed with R software, version 3.4.3 (R, College Station, TX).

Overview. As seen in Fig. 1 , a total of 682 studies were identified from four databases. 312 were determined to be duplicates, leaving 370 for the initial screening of titles and abstracts. 262 were then excluded based on the abstract. Of the 108 full-text articles screened, an additional 86 were excluded, leaving a total of 22 studies included for the analysis. These studies represented North America, Africa, Europe, and Asia. The articles that were ultimately included contained a total of 20,982,498 sample size. Table 1 summarizes the study-level sociodemographic variables of the study sample and diagnostic criteria for COVID-19 (clinical and laboratoryconfirmed by PCR). The median age of the patients included in the study was 56 years. On average, 66.0% of the participants were male. The most common comorbidities in the HIV-positive population were hypertension, diabetes, chronic obstructive pulmonary disease and chronic kidney disease. Overall, the median CD4 count was 538 cells/μL. Over 96% of PLWHA were on ARV therapy, and over 80% of the HIV-positive patients were virally suppressed (than 50 copies of HIV/mL). All studies except one reported diagnosis of COVID-19 with SARS-CoV-2 RNA reverse transcription PCR (RT-PCR) of nasopharyngeal or throat swabs.

HIV was associated with a significantly higher risk of SARS-CoV-2 infection (RR 1.24, 95% CI 1.05-1.46; Fig. 2 ). Between-study variation was high (I 2 = 85, p = 0.0003). The pooled prevalence of HIV in COVID-19 patients was 1.22% (95% CI 0.61-2.43%; Fig. 3b ; I 2 = 98%; p < 0·01). The prevalence of HIV in COVID-19 patients ranged from a low of 0.26% (95% CI 0.23-0.29%) in Catalonia, Spain to a high of 4.17% (95% CI 0.58-24.35%) in Seattle, USA. The point estimates for the prevalence of HIV of the general population in the analyzed cities was half the HIV prevalence in among COVID-19 patients: 0.65% (95% CI 0.48-0.89%; Fig. 3a ). When we stratified the analysis by the country (Fig. 4) , we found a noticeable difference in the pooled HIV prevalence among COVID-19 patients in the United Sates (1.43%, 95% CI 0.98-2.07%) compared to Spain (0.26%, 95% CI 0.23-0.29%) but the difference was not significant compared to the prevalence in China (0.99%, 95% CI 0.25-3.85%).

The overall pooled RR of COVID-19 mortality associated with HIV was 1.78 (95% CI 1.21-2.60), implying there is nearly an 80% excess risk of death among HIV patients as compared to the individuals without HIV/AIDS. Between-study variation was moderate (I 2 = 78, p = 0.002; Fig. 5 ). The pooled mortality rate among HIV positive patients was 12.65% (95% CI 6.81-22.31%, I 2 = 74%; p < 0.01; Fig. 6 ). The pooled mortality rate ranged from a high of 35% (95% CI 10-72%) in the United States to a low of 4% (95% CI 1.07-15.48%; Fig. 6 ) in Italy. Tesoriero 

umented the risk of COVID-19 diagnosis and severity by ARV therapy. In a study by del Almo and colleagues, after stratification by NRTI regimen, persons receiving tenofovir disoproxil fumarate/emtricitabine ( TDF/FTC) had the lowest risk for COVID-19 diagnosis (16.9 per 10,000), hospitalization (10.5 per 10,000), ICU admission (0 per 10,000) and death (0 per 10,000) 35 . However, in the adjusted multivariable logistic regression model, Vizcarra and colleagues found that higher use of tenofovir before the COVID-19 pandemic was associated with nearly fourfold greater risk for the diagnosis of COVID-19 (OR 3.7 [95% CI 1.6-8.7]) 29 . Furthermore, Haerter and colleagues did not find clear evidence for a protective effect of tenofovir and boosted darunavir-based ARV therapy 16 . In addition, the results from a France study did not support a protective role of tenofovir against COVID-19 32 . All 5 patients reported in the study by Blanco received boosted-protease inhibitor ARV therapy, with the rationale that HIV protease inhibitors might have activity against the coronavirus protease. By the reporting of their study findings, no patient had died 17 . Study quality, publication bias and sensitivity analyses. The median study quality score was 8 out of 9 (range: 7-8; Table 1 ). Visual inspection of funnel plot shows clear evidence of asymmetry (Supplemental Fig. 2 ). Egger's test for asymmetry was significant (p = 0.005), indicative of possible publication bias. 

This meta-analysis found that persons living with HIV have a higher risk of SARS-CoV-2 infection and mortality risk from COVID-19 than people without HIV. Furthermore, our estimates suggest the prevalence of HIV in COVID-19 patients and associated mortality vary globally.

Preexisting chronic conditions such as hypertension, diabetes, and cardiovascular diseases are prevalent in PLWHA, and given these comorbidities play a significantly influential role in COVID-19 severity 3 , PLWHA, even on ARV therapy, may still present with a compromised immune system, and subsequently have an increased risk of COVID-19 and associated adverse outcomes. In addition to immunosuppression associated with HIV/AIDS, PLWHA are at risk of anemia, neutropenia, thrombocytopenia, and abnormal serum electrolytes 36 , which also play a critical role in the disease course of COVID-19. Hence, it remains vital for PLWHA to retain regular HIV care and maintain good adherence to ARV therapy.

The mean age of HIV-positive patients with COVID-19 was 55 years, which is a decade younger than the mean age of hospitalized COVID-19 patients in the general population. The substantial difference in age of COVID-19 www.nature.com/scientificreports/ results from the effect of premature aging of PLWHA due to chronic inflammation associated with HIV infection or high prevalence of certain behavioral risk factors (e.g., smoking). Consequently, the rate of comorbidities that are commonly seen in older, non-HIV populations (such as cardiovascular disease) are prevalent in PLWHA at a much younger age 37 . PLWHA are generally characterized by a dysregulated immune system. A rapid and well-coordinated innate immune response provides a vital defense system against viral infections 38 . It remains crucial to maintain a balance in the immune system, characterized by a balance in CD4 cell subpopulations that consist of effector-T cells and memory T-cells 39 www.nature.com/scientificreports/ cytokines and chemokines leading to an increase in the severity of COVID-19 infections, higher consumption of CD4+ and CD8+ T-cells, decrease in regulatory T-cells, and a altered innate immune environment leading to a cytokine storm and worsen damaged tissue 40, 41 . In addition, evidence also suggests that subgroups of COVID-19 patients might suffer from hyperinflammatory syndrome termed as secondary hemophagocytic lymphohistiocytosis (sHLH) that is often triggered by underlying viral infections or sepsis and leads to fulminant and fatal hypercytokinaemia with multiorgan failure 41 . Though the incidence of sHLH among patients with HIV might be rare, coinfection of HIV patients with COVID-19 might result in sHLH leading to heightened severity of disease and high mortality. An important component and determinant of HIV infections involves not only CD4 count but also viral load and access and adherence to ARV therapy, which remains an essential aspect of long-term outcomes, including progression to AIDS and survival among HIV patients 42 . Non-adherence to ARV therapy has shown to be associated with low CD4 count, high viral load, and risk of AIDS and death 43 . Among PLWHA, hospitalization risk increased with disease progression and for those virally unsuppressed 6 . Although some ARV therapies have been proposed to protect against COVID-19, the data remain uncertain. In molecular docking studies, tenofovir has been recently shown to bind to SARS-CoV-2 RNA polymerase (RdRp) with binding energies comparable to those of native nucleotides and to a similar extent as remdesivir 44 . Observational studies have indicated a potential benefit of protease-inhibitors (lopinavir or ritonavir) in COVID-19 by slowing the disease's progression and improving the prognosis of patients 45 . However, in a randomized controlled open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, no benefit was observed with lopinavir-ritonavir treatment beyond standard care 46 . In the current study, the protective effect of tenofovir or protease-inhibitors remains inconclusive. 

The strength of the current study is the global representation in the included articles assessing HIV/SARS-CoV-2 coinfection and estimated the attack and mortality rate in PLWHA compared to those who are HIV-negative. Thus, the findings from the current analysis are generalizable. Nevertheless, a lack of detailed study-level clinical and sociodemographic information did not allow us to perform subgroup and meta-regression analyses to explore the influence of stage of HIV, levels of CD4 counts or HIV viral load and ARV therapy regimen and treatment adherence on the incidence and severity of COVID-19 in HIV-positive persons. Furthermore, residual confounding by comorbid conditions cannot be excluded entirely. Therefore, future studies might consider assessing how the association between HIV and severe COVID-19 outcomes is moderated or mediated by comorbidities, HIV viral load, CD4 count, and ARV therapy. Lastly, although most studies only included laboratory-confirmed COVID-19 patients, a few studies combined laboratory-confirmed and clinically diagnosed (probable) cases. Therefore, it is possible that nondifferential misclassification of exposure could have affected the observed associations. 

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis

Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: Systematic review and meta-analysis

Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis

Elevated COVID-19 outcomes among persons living with diagnosed HIV infection in New York State: Results from a population-level match of HIV, COVID-19, and hospitalization databases

Epidemiological, virological and serological features of coronavirus disease 2019 (COVID-19) cases in people living with human immunodeficiency virus in Wuhan: A population-based cohort study

A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan, China. AIDS Patients in Two Districts of Wuhan

Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: A systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses

Random-effects model for meta-analysis of clinical trials: An update

Measuring inconsistency in meta-analyses

Bias in meta-analysis detected by a simple, graphical test

COVID-19 in people living with human immunodeficiency virus: A case series of 33 patients

COVID-19 in patients with HIV: Clinical case series

Clinical features and outcomes of HIV patients with coronavirus disease 2019

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: A single-centered, retrospective study

Outcomes among HIV-positive patients hospitalized with COVID-19

Covid-19 in critically ill patients in the Seattle region-Case series

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study

Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series

Characteristics and outcomes of COVID-19 patients in New York City's public hospital system

Investigation of subsequent and coinfections associated with SARS-CoV-2 (COVID-19) in hospitalized patients

Clinical features and outcome of HIV/SARS-CoV-2 coinfected patients in the Bronx

Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort

HIV infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

Coronavirus disease 2019 attack rate in HIV-infected patients and in preexposure prophylaxis users

COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: The MACS/WIHS combined cohort study

Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): A prospective observational study

Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: A cohort study

Hematological abnormalities in HIV-infected patients

Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study

Age-dependent dysregulation of innate immunity

When aging reaches CD4+ T-cells: Phenotypic and functional changes

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

COVID-19: Consider cytokine storm syndromes and immunosuppression

Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents

Self-reported non-adherence to ART and virological outcome in a multiclinic UK study

Remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

/scientificreports/ Reprints and permissions information is available at www.nature.com/reprints

Heterogeneity: I 2 = 74%, τ 2 = 0.5781, p < 0.01 Residual heterogeneity: I 2 = 75%, p < 0.01 The study's funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-85359-3.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.